Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.39 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.39 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.39 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.39 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.39 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.39 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.39 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 10/20 | 0.37 |
| ▸ | MAOA | P21397 | 10/20 | 0.37 |
| ▸ | MAOB | P27338 | 10/20 | 0.37 |
| ▸ | SGPL1 | O95470 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993041 | 0.90 | SLC18A3 (0.40) | TRPA1KDM1AMAOAMAOBSLC18A3 | |
| SCHEMBL27163338 | 0.79 | TRPA1 (0.43) | TRPA1ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL4601566 | 0.74 | HTR3A (0.38) | KDM1ASLC18A3 | |
| SCHEMBL4601344 | 0.74 | ESR2 (0.37) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL4600362 | 0.72 | DRD2 (0.42) | KDM1AMAOAMAOB | |
| SCHEMBL4600111 | 0.71 | HTR2C (0.54) | KDM1A | |
| SCHEMBL12381916 | 0.70 | TRPA1 (0.54) | TRPA1ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL6937542 | 0.70 | GRM4 (0.49) | TRPA1SGPL1 | |
| SCHEMBL4407230 | 0.69 | KDM1A (0.50) | KDM1AMAOAMAOB | |
| Formic Acid SCHEMBL27499337 | 0.69 | TRPA1 (0.53) | TRPA1ATP1A1ATP1B1ATP1A3ATP1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296938-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | TRPA1 4084/4885ATP1A1 1900/4885ATP1B1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.